| Primary |
| Lung Neoplasm Malignant |
51.2% |
| Deep Vein Thrombosis |
8.0% |
| Pulmonary Embolism |
8.0% |
| Thrombosis Prophylaxis |
4.4% |
| B Precursor Type Acute Leukaemia |
4.1% |
| Anticoagulant Therapy |
2.3% |
| Non-small Cell Lung Cancer |
2.3% |
| Asthma |
2.1% |
| Chronic Obstructive Pulmonary Disease |
2.1% |
| Percutaneous Coronary Intervention |
2.1% |
| Hypertension |
1.8% |
| Pain |
1.8% |
| Diabetes Mellitus |
1.5% |
| Non-small Cell Lung Cancer Stage Iv |
1.5% |
| Embolism Venous |
1.3% |
| Ill-defined Disorder |
1.3% |
| Type 2 Diabetes Mellitus |
1.3% |
| Acute Myocardial Infarction |
1.0% |
| Cancer Pain |
1.0% |
| Chemotherapy |
1.0% |
|
| Dyspnoea |
7.3% |
| Thrombocytopenia |
7.3% |
| Vomiting |
7.3% |
| White Blood Cell Count Increased |
7.3% |
| Platelet Count Decreased |
6.4% |
| Pyrexia |
6.4% |
| Anaemia |
4.6% |
| Haemorrhage |
4.6% |
| Pain |
4.6% |
| Pancytopenia |
4.6% |
| Pulmonary Embolism |
4.6% |
| Sepsis |
4.6% |
| White Blood Cell Count Decreased |
4.6% |
| Cellulitis |
3.7% |
| Epistaxis |
3.7% |
| Fatigue |
3.7% |
| Gastrointestinal Haemorrhage |
3.7% |
| Haemoglobin Decreased |
3.7% |
| Haemoptysis |
3.7% |
| Nausea |
3.7% |
|
| Secondary |
| Product Used For Unknown Indication |
23.0% |
| Drug Use For Unknown Indication |
17.4% |
| Suicide Attempt |
9.7% |
| Lung Neoplasm Malignant |
7.5% |
| Deep Vein Thrombosis |
5.4% |
| T-cell Type Acute Leukaemia |
5.4% |
| Overdose |
4.6% |
| Type 2 Diabetes Mellitus |
4.5% |
| Diabetes Mellitus |
3.4% |
| Thrombosis Prophylaxis |
2.7% |
| Embolism |
2.4% |
| Pulmonary Embolism |
2.2% |
| Idiopathic Thrombocytopenic Purpura |
2.1% |
| Antiphospholipid Syndrome |
1.9% |
| Hypertension |
1.8% |
| Dermatomyositis |
1.4% |
| Ill-defined Disorder |
1.2% |
| Atrial Fibrillation |
1.2% |
| Colorectal Cancer Metastatic |
1.2% |
| Urinary Tract Infection |
1.2% |
|
| Suicide Attempt |
14.0% |
| Renal Failure |
10.0% |
| Lung Cancer Metastatic |
8.0% |
| Overdose |
6.7% |
| Thrombocytopenia |
6.0% |
| Gastrointestinal Haemorrhage |
5.3% |
| Haemorrhage |
5.3% |
| Coagulopathy |
4.0% |
| Dehydration |
4.0% |
| Large Intestine Perforation |
4.0% |
| Peritonitis |
4.0% |
| Pulmonary Haemorrhage |
4.0% |
| Somnolence |
4.0% |
| Drug Interaction |
3.3% |
| Premature Rupture Of Membranes |
3.3% |
| Pulmonary Embolism |
3.3% |
| Ascites |
2.7% |
| Constipation |
2.7% |
| Thrombosis In Device |
2.7% |
| Upper Gastrointestinal Haemorrhage |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.1% |
| Drug Use For Unknown Indication |
16.0% |
| Prophylaxis |
13.4% |
| Infection Prophylaxis |
7.4% |
| Bone Marrow Conditioning Regimen |
5.0% |
| Prophylaxis Against Graft Versus Host Disease |
4.1% |
| Premedication |
3.5% |
| Pneumonia |
2.8% |
| Hypertension |
2.7% |
| Constipation |
2.5% |
| Interstitial Lung Disease |
2.4% |
| Antifungal Prophylaxis |
2.2% |
| Prophylaxis Of Nausea And Vomiting |
2.0% |
| Thrombosis Prophylaxis |
1.8% |
| Disseminated Intravascular Coagulation |
1.7% |
| Pain |
1.6% |
| Multiple Myeloma |
1.5% |
| Pulmonary Embolism |
1.4% |
| Analgesic Therapy |
1.4% |
| Nausea |
1.4% |
|
| Vomiting |
11.6% |
| Pulmonary Embolism |
9.5% |
| Thrombocytopenia |
8.4% |
| Renal Failure |
8.1% |
| Pyrexia |
7.0% |
| Sepsis |
6.0% |
| Liver Function Test Abnormal |
5.6% |
| Renal Failure Acute |
4.9% |
| Deep Vein Thrombosis |
4.6% |
| Respiratory Failure |
3.9% |
| Death |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| Pancytopenia |
3.2% |
| Pneumonia |
3.2% |
| Staphylococcal Sepsis |
3.2% |
| Myositis |
2.8% |
| Renal Failure Chronic |
2.8% |
| Renal Impairment |
2.8% |
| Rhabdomyolysis |
2.8% |
| Toxic Epidermal Necrolysis |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
67.3% |
| Deep Vein Thrombosis |
25.0% |
| Atrial Fibrillation |
3.8% |
| Product Used For Unknown Indication |
3.8% |
|
| Drug Interaction |
93.3% |
| Operative Haemorrhage |
6.7% |
|
